Pharmacological characterization of the discriminative stimulus properties of the phencyclidine analog, N-[1-(2-benzo(b)thiophenyl)-cyclohexyl]piperidine.
BACKGROUND
Although both cocaine and the phencyclidine analog, BTCP, have dopamine (DA) re-uptake blocking properties, under some conditions their behavioral effects can be differentiated. Therefore, we examined whether the discriminative stimulus (DS) effects of BTCP are different from those of cocaine.


OBJECTIVE
To compare the effects of monoamine re-uptake blockers, varying in their in vitro potencies as inhibitors of DA, norepinephrine (NE), or serotonin re-uptake, in different groups of rats trained to discriminate either BTCP or cocaine from saline. Additionally, drugs from other pharmacological classes were tested in both groups.


METHODS
Rats were trained to discriminate either BTCP (5 mg/kg, i.p.) or cocaine (10 mg/kg, i.p.) from saline under a two-lever FR10 drug discrimination procedure.


RESULTS
BTCP and cocaine cross-substituted in BTCP- and cocaine-trained rats. The DA re-uptake blockers, mazindol, indatraline, methylphenidate, GBR12909, and GBR12935, occasioned dose-related drug-lever (DL) selection both in cocaine- and in BTCP-trained rats, with potencies that were significantly correlated. In contrast, the NE re-uptake blockers, nisoxetine, desipramine, and nortriptyline, produced higher levels of DL selection in BTCP-trained rats than in cocaine-trained rats, a profile like that reported in low-dose cocaine-trained rats. Drugs from other classes acted similarly in both discriminations. Further, the alpha1-adrenergic antagonist prazosin dose dependently blocked the DS effects of the training dose of BTCP, but not of cocaine.


CONCLUSIONS
The results suggest that the DS effects of BTCP are similar to cocaine, and resemble those of a low training dose of cocaine.
Kleven
M S
MS
Centre de Recherche Pierre Fabre, 17 avenue Jean Moulin, F-81106 Castres Cedex, France.kleven@ilink.fr
Kamenka
J M
JM
Vignon
J
J
Koek
W
W
D000818:Animals; D003042:Cocaine / Q000494:pharmacology; D004193:Discrimination Learning / Q000187:drug effects*; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D008297:Male; D009638:Norepinephrine / Q000502:physiology; D010622:Phencyclidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology
D003042:Cocaine; D018765:Dopamine Uptake Inhibitors; D009638:Norepinephrine; D010622:Phencyclidine; D011224:Prazosin; D017367:Selective Serotonin Reuptake Inhibitors; C056415:1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine